Clinical Trial Update: Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1≥ 50% [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating capmatinib plus pembrolizumab versus pembrolizumab alone in non-small cell lung cancer with PD-L1 expression ≥50%; the study was termin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Capmatinib (INC280) (capmatinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Status: TERMINATED | Results posted: 2024-02-08